Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients

Bibliography

• Magagna A, Abdel-Haq B, Favilla S, et al. Indomethacin raises blood pressure in untreated essential hypertensives: a double-blind randomly allocated study vs placebo. J Hypertens 1991;9(Suppl):S42-3
   Google Scholar
• Pope JE, Andersen JJ, Felson DT. A meta-analysis of the effects of non steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84
   PubMed Web of Science ®Google Scholar
• Johnson A, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300
   PubMed Web of Science ®Google Scholar
• Salvetti A, Abdel-Haq B, Magagna A, Pedrinelli R. Indomethacin reduces the antihypertensive effect of enalapril. Clin Exp Hypertens A 1987;9:559-67
   PubMed Web of Science ®Google Scholar
• Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000;13:1161-7
   PubMed Web of Science ®Google Scholar
• Conlin PR, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000;36:461-5
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Carretta R, et al. on behalf of the Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. J Hypertens 2002;20:1007-14
   PubMed Web of Science ®Google Scholar
• Palmer R, Weiss R, Zusman RM, et al. Effects of nabumetone, celecoxib and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003;16:135-9
   PubMed Web of Science ®Google Scholar
• Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32:1-12
   PubMed Web of Science ®Google Scholar
• Oates JA, Fitzgerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988;319:689-98
   PubMed Web of Science ®Google Scholar
• Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013. [Epub ahead of print]
   Google Scholar
• Hermann M. Cardiovascular risk associated with non steroidal anti-inflammatory drugs. Curr Rheumatol Rep 2009;11:31-5
   PubMedGoogle Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A, et al. Use of non steroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42
   PubMed Web of Science ®Google Scholar
• Sudano I, Flammer AJ, Périat D, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010;122:1789-96
   PubMed Web of Science ®Google Scholar
• Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167:394-9
   PubMed Web of Science ®Google Scholar
• Forman JP, Stamfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7
   PubMed Web of Science ®Google Scholar
• Chalmer JP, West MJ, Wing LM, et al. Effects of indomethacin, sulindac, naproxen, aspirin and paracetamol in treated hypertensive patients. Clin Exp Hypertens 1984;6:1077-93
   Google Scholar
• Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med 1987;107:628-35
   PubMed Web of Science ®Google Scholar
• Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled Trial. Can J Clin Pharmacol 2008;15:e372-82
   PubMedGoogle Scholar
• Mac Kenzie IS, MacDonald TM. Treatment of osteoarthritis in hypertensive patients. Expert Opin Pharmacother 2010;11:393-403
   PubMedGoogle Scholar
• Senn S. Cross-over trials in clinical research. 1st edition. John Wiley; New York: 1993
   Google Scholar
• Groppelli A, Omboni S, Ravogli A, et al. Validation of the Spacelabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements. J Hypertens 1991;9(suppl 3):S334-5
   Google Scholar
• Parati G, Bosi S, Castellano M, et al. Guidelines for 24-hour non invasive ambulatory blood pressure monitoring: report from a working group of the Italian Society of Hypertension. High Blood Press 1995;4:168-74
   Google Scholar
• Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999;33(6):1406-13
   PubMedGoogle Scholar
• Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 1987;5:121-8
   PubMed Web of Science ®Google Scholar
• Zusman RM. Effects of converting enzyme inhibition on the renin-angiotensin-aldosterone, bradykinin and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis 1987;10(Suppl 1):13-23
   PubMedGoogle Scholar
• Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997;100:264-9
   PubMed Web of Science ®Google Scholar
• Volpe M, De Paolis P. Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy. Ital Heart J 2000;1:96-103
   PubMedGoogle Scholar
• Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925-35
   PubMed Web of Science ®Google Scholar
• Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410
   PubMed Web of Science ®Google Scholar
• Mattammal MB, Zenser TV, Brown WW, et al. Mechanism of inhibition of renal prostaglandin by acetaminophen. J Pharmacol Exp Ther 1979;210:405-9
   PubMedGoogle Scholar
• Graham GC, Scott KF. Mechanism of action of paracetamol. Am J Ther 2005;12:46-55
   PubMedGoogle Scholar
• Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240:410-11
   PubMed Web of Science ®Google Scholar
• Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006;79(1):9-19
   PubMedGoogle Scholar
• Chandrasekharan NV, Dai H, Roos KL, et al. COX-3,a ciclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 2002;99:13926-31
   PubMed Web of Science ®Google Scholar
• Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxigenase-2 inhibitor in man. FASEB J 2008;22:383-90
   PubMed Web of Science ®Google Scholar
• Bertolini A, Ferrari A, Ottani A, et al. Paracetamol: new vistas of an old drug. CNS Drug Rev 2006;12:250-75
   PubMedGoogle Scholar
• Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? Ann Rheum Dis 2012;71(1):20-5
   PubMed Web of Science ®Google Scholar
• Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701-9
   PubMed Web of Science ®Google Scholar
• Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease and death: the NHANES-I epidemiologic follow-up study. Am Heart J 1993;125:1148-54
   PubMedGoogle Scholar
• Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997;15:3-17
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64(4):465-74
   PubMed Web of Science ®Google Scholar